These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 20719377)

  • 1. Gout therapeutics: new drugs for an old disease.
    Burns CM; Wortmann RL
    Lancet; 2011 Jan; 377(9760):165-77. PubMed ID: 20719377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Gout: an overview of available urate lowering therapies].
    Richette P
    Ann Pharm Fr; 2012 May; 70(3):133-8. PubMed ID: 22655581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on emerging urate-lowering therapies.
    Chohan S; Becker MA
    Curr Opin Rheumatol; 2009 Mar; 21(2):143-9. PubMed ID: 19339925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel drug discovery strategies for gout.
    Richette P; Garay R
    Expert Opin Drug Discov; 2013 Feb; 8(2):183-9. PubMed ID: 23231400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
    Ernst ME; Fravel MA
    Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urate-lowering therapy for gout: focus on febuxostat.
    Love BL; Barrons R; Veverka A; Snider KM
    Pharmacotherapy; 2010 Jun; 30(6):594-608. PubMed ID: 20500048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New therapeutic options for gout].
    Richette P; Ottaviani S; Bardin T
    Presse Med; 2011 Sep; 40(9 Pt 1):844-9. PubMed ID: 21684104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in management of gout.
    Suresh E; Das P
    QJM; 2012 May; 105(5):407-17. PubMed ID: 22198943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New gout treatment approved.
    Traynor K
    Am J Health Syst Pharm; 2009 Apr; 66(7):606. PubMed ID: 19299362
    [No Abstract]   [Full Text] [Related]  

  • 10. Febuxostat (Uloric) for chronic treatment of gout.
    Med Lett Drugs Ther; 2009 May; 51(1312):37-8. PubMed ID: 19448587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of available urate-lowering drugs: a critical review.
    Strilchuk L; Fogacci F; Cicero AF
    Expert Opin Drug Saf; 2019 Apr; 18(4):261-271. PubMed ID: 30915866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging therapies for gout.
    Edwards NL; So A
    Rheum Dis Clin North Am; 2014 May; 40(2):375-87. PubMed ID: 24703353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in pharmacotherapy for the treatment of gout.
    Robinson PC; Dalbeth N
    Expert Opin Pharmacother; 2015 Mar; 16(4):533-46. PubMed ID: 25547991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Febuxostat: new drug. Hyperuricaemia: risk of gout attacks.
    Prescrire Int; 2009 Apr; 18(100):63-5. PubMed ID: 19585722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Febuxostat: a novel non-purine selective inhibitor of xanthine oxidase for the treatment of hyperuricemia in gout.
    Yu KH
    Recent Pat Inflamm Allergy Drug Discov; 2007 Feb; 1(1):69-75. PubMed ID: 19075968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Febuxostat: a new agent for lowering serum urate.
    Keenan RT; Pillinger MH
    Drugs Today (Barc); 2009 Apr; 45(4):247-60. PubMed ID: 19499090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Febuxostat].
    Wittköpper K; Emons J; El-Armouche A
    Dtsch Med Wochenschr; 2011 Jun; 136(23):1270-4. PubMed ID: 21607898
    [No Abstract]   [Full Text] [Related]  

  • 20. Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors.
    Goldfarb DS; MacDonald PA; Hunt B; Gunawardhana L
    J Rheumatol; 2011 Jul; 38(7):1385-9. PubMed ID: 21572152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.